PMID: 2502649Jul 3, 1989Paper

Antibody mediated thrombolysis. A new therapeutic principle

Klinische Wochenschrift
C Bode, W Kübler

Abstract

Thrombosis of a coronary artery is the most common cause of myocardial infarction. Thrombolytic therapy, when instituted timely, has been shown capable of reducing morbidity and mortality. However, the use of presently available thrombolytic agents is associated with a bleeding tendency and efficacy is not optimal. This article reviews one of several lines of investigation that are presently being pursued in order to improve efficacy and specificity of thrombolytic therapy. The chemical conjugation of a fibrin specific monoclonal antibody and urokinase or tissue plasminogen activator results in markedly enhanced thrombolytic potency, both in vitro and in vivo. Specificity of the conjugates is greater than that of the parent plasminogen activators as reflected by conservation of fibrinogen, plasminogen and alpha-2 antiplasmin. A bispecific antibody, with specificity for both, fibrin and tissue plasminogen activator, has the potential of concentrating endogenous tissue plasminogen activator at the site of a thrombus. In the presence of the bispecific antibody, efficacy and specificity of tissue plasminogen activator are markedly enhanced in vitro and in vivo. The tools of molecular biology are presently being applied in order to ...Continue Reading

References

Feb 1, 1986·Annals of Internal Medicine·R A DePinhoM D Scharff
Aug 1, 1987·The American Journal of Cardiology·C BodeW Kuebler
Oct 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·J M SchneeT Quertermous
Nov 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·M S RungeE Haber
Apr 1, 1987·Journal of Molecular and Cellular Cardiology·C BodeE Haber
Sep 11, 1986·The New England Journal of Medicine·C M Pinsky
Jun 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·B E SobelS J Sarnoff
Oct 17, 1985·The New England Journal of Medicine·S Sherry
Apr 4, 1985·The New England Journal of Medicine·UNKNOWN TIMI Study Group
Nov 1, 1985·The Journal of Clinical Investigation·E Braunwald, R A Kloner
Jan 1, 1973·Advances in Protein Chemistry·R F Doolittle
Dec 13, 1984·Nature·M S NeubergerR O Fox
Sep 13, 1984·The New England Journal of Medicine·G L Laffel, E Braunwald
Mar 8, 1984·The New England Journal of Medicine·F Van de WerfB E Sobel
Oct 16, 1980·The New England Journal of Medicine·M A DeWoodH T Lang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.